BRIUMVI Momentum Lifts TG Therapeutics: A 2026 Revenue Forecast Re-Write for TGTX

Executive snapshot

TG Therapeutics, Inc. (ticker: TGTX) reports a first quarter 2026 that looks like a one-two punch for a biotech that leans heavy on a single product. Total revenue for the quarter came in around $205 million, with U.S. net revenue from BRIUMVI (ublituximab-xiiy) pegged at about $194.8 million. That line item implies roughly 63% year-over-year growth, a fact the company frames as validation of demand, not just a one-off spike tied to a marketing push. The press release is light on EPS figures, which means analysts will be left to work out the implied profitability from the revenue growth and cost structure. Still, the headline here is revenue momentum, not a sterling earnings per share number.

TG Therapeutics also used the moment to lift its revenue guidance for 2026. The company now targets total global revenue of about $925 million and raises the BRIUNVI U.S. net product revenue target to roughly $885–$900 million. It’s a bold step, but one that follows the quarterly performance and the ongoing sales trajectory of BRIUMVI in the U.S. market. On the earnings-frontier question, the release does not provide an EPS readout, so the EPS consensus from analysts will hinge on how costs and other revenue streams shape up through the year. If investors are expecting an earnings surprise tied to higher revenue, the street will be watching for margin expansion or contraction in subsequent quarters to justify a different EPS trajectory.

Revenue momentum and quantitative takeaways

The quarterly numbers underscore BRIUMVI’s role as TG Therapeutics' revenue backbone. A U.S. net product revenue near $195 million in Q1 2026 signals a robust launch run, especially when paired with sustained domestic demand. The company’s revenue forecast for 2026 now sits at roughly $925 million, with BRIUMVI’s U.S. contribution guided to $885–$900 million. For investors, this sets up a narrative where the top line is pulling the heavier weight while margin dynamics remain a function of cost of goods sold, marketing, and amortization of upfront investments.

In terms of market reaction, a guided raise typically signals management confidence in execution. The question for the equity view is whether the incremental revenue will translate into material earnings per share acceleration, or if operating costs will offset some of that push. In the absence of an explicit EPS figure from the release, the EPS consensus across sell-side models will hinge on how quickly the company can translate revenue growth into operating leverage.

Data presentations and publications

TG Therapeutics is anchoring the quarter with external data momentum as well. The company reports two journal publications highlighting ublituximab data:

• March 2026: “Efficacy of Ublituximab in People with Highly Active Relapsing Multiple Sclerosis,” published in Neurology and Therapy, with a post hoc pooled analysis from ULTIMATE I and II suggesting meaningful activity in highly active RMS.
• February 2026: “Five Years of Ublituximab in Multiple Sclerosis: ULTIMATE I and II Open-Label Extension (OLE) Study,” published in JAMA Neurology, detailing five-year data from the open-label extension.

These publications reinforce BRIUMVI’s clinical traction, a factor investors will weigh alongside the revenue plan. A pair of long-horizon data catalysts can influence both the revenue forecast plausibility and the broader perception of the product’s durability in the MS franchise.

Pipeline progress and near-term catalysts

Beyond BRIUMVI’s commercial trajectory, TG Therapeutics flags ongoing clinical activities designed to broaden the franchise. Highlights include:

• Completed patient enrollment into the randomized Phase 3 pivotal program evaluating subcutaneous BRIUMVI, which could accelerate administration convenience and payer acceptance.
• Completed patient enrollment into a Phase 3 pivotal program to evaluate a consolidated Day 1 and Day 15 IV BRIUMVI dosing regimen within the ENHANCE trial, potentially simplifying IV administration protocols.
• Continued enrollment in an ongoing Phase 1 trial evaluating azer-cel for autoimmune diseases, expanding the clinical pipeline beyond MS and potentially diversifying long-term growth drivers.

Taken together, these milestones imply multiple near-term clinical readouts that could act as catalysts for the stock if the outcomes align with or exceed expectations. The path to a broader MS portfolio and adjacent indications hinges on whether these strategies translate into comparable top-line upside without eroding margin discipline.

Guidance, economics, and what it means for peers

The raised revenue targets reflect a management team that remains confident in BRIUMVI’s commercial uptake and in the platform’s ability to execute against a growing MS market. The revenue forecast now points to a high-trajectory year, with EPS implications contingent on cost control and operating leverage. If analysts forward-model the expense profile conservatively, TG Therapeutics could see an earnings trajectory that proves more durable than a headline revenue number might imply.

For sector peers, the report underscores a few takeaways:

• Product-level leadership and payer access matter as much as trial progress in driving earnings visibility.
• Transitioning patients to subcutaneous formats can unlock broader adoption, potentially boosting volume without proportional increases in administration costs.
• Data catalysts from ongoing Phase 3 programs and long-term extensions can meaningfully influence valuation, even when EPS is still taking shape in the quarterly cadence.

What to watch next

The key question remains: will the revenue momentum translate into sustained profitability and margin expansion? The absence of a disclosed EPS figure means investors will survey cost structures, R&D intensity, and any one-time items across quarters to triangulate the true earnings trajectory. Down the line, the potential introduction of a subcutaneous formulation and the results from ENHANCE and azer-cel trials could compound the company’s growth narrative and invite comparisons with peers pursuing similar MS franchises or autoimmune programs.

TG Therapeutics will host a conference call on May 6, 2026, at 8:30 AM ET to discuss results and forward-looking plans. As always, the stock’s reaction will hinge on the degree to which management’s narrative aligns with the street’s EPS consensus and the market’s appetite for caution or exuberance around 2026’s revenue forecast.